Welcome to our dedicated page for SERA PROGNOSTICS SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
SERA filed a Form 144 reporting Restricted Stock Unit vesting for Class A Common stock on 03/09/2026. The filing also records a prior resale of 1,332 shares on 12/10/2025. The notice lists numbers tied to the securities and intermediary details.
SERA notice of proposed sale of Class A Common shares tied to Restricted Stock Unit vesting.
The filing lists securities to be sold on 03/09/2026 arising from Restricted Stock Unit vesting. It also reports prior sales by Austin Aerts: 12/09/2025 (5,232 shares) and 12/10/2025 (873 shares) as shown in the table.
SERA PROGNOSTICS, INC. director Sandra AJ Lawrence reported an open-market sale of 1,560 shares of Class A common stock at a weighted average price of $1.95 per share. The sale was made under a Rule 10b5-1 trading plan adopted on June 10, 2025. After this transaction, she directly holds 18,033 shares.
SERA filed a Form 144 reporting a proposed sale of 1,560 shares of common stock.
The filing identifies the securities as Restricted Stock Units dated 01/05/2026 and records prior 10b5-1 sales by Sandra A J Lawrence of 1,560 shares on 12/08/2025. The notice lists NASDAQ as the market and 03/06/2026 appears as a filing reference date.
SERA PROGNOSTICS, INC. Chief Information Officer Harrison Robert Gardner reported an open-market sale of 2,000 shares of Class A Common Stock. The shares were sold at a weighted average price of $2.34 per share, in transactions ranging from $2.23 to $2.45. After this sale, Gardner directly holds 80,788 shares of Sera Prognostics common stock. The transaction was carried out under a pre-established Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2025, which is designed to systematically execute trades according to preset instructions.
Robert Harrison filed a Form 144 reporting a proposed sale of 2,000 Common shares (listed as Restricted Stock Units) through Morgan Stanley Smith Barney LLC. The filing also lists recent 10b5-1 sales: 2,000 shares on 01/27/2026, 2,000 on 12/30/2025, 616 on 12/10/2025, and 2,000 on 12/02/2025.
Sera Prognostics, Inc. director Kim P. Kamdar reported a restructuring of her holdings through a pro rata distribution by Domain Associates, LLC. Domain Associates distributed 30,920 shares of Class A common stock it held for her indirect benefit, for no consideration, reducing her indirect holdings to zero. As part of the same distribution, Kamdar received 3,231 shares of Class A common stock directly, also for no consideration, bringing her directly held stake to 32,573 shares. The transactions are coded as “J,” reflecting the internal reallocation and not a market purchase or sale.
Sera Prognostics, Inc. insider Harrison Robert Gardner, the company’s Chief Information Officer, reported selling 2,000 shares of Class A common stock on January 27, 2026 at a reported price of $2.97 per share. After this transaction, he beneficially owned 82,788 shares directly.
The sale was carried out under a pre-established Rule 10b5-1 trading plan that Gardner adopted on May 21, 2025. The filing notes the reported price is a weighted average, with individual trades executed between $2.92 and $3.06 per share.
A holder of Common stock has filed a notice of proposed sale of 2,000 shares, with an aggregate market value of $6,180.00, through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/27/2026 on the NASDAQ. The issuer has 37,627,034 shares of this class outstanding. The shares to be sold were acquired as Restricted Stock Units from the issuer on 02/06/2024, in an amount of 2,000 shares.
Over the prior three months, the same account reported several sales of the issuer’s common stock, including 2,000 shares for $6,002.60 on 12/30/2025, 616 shares for $2,038.96 on 12/10/2025, 2,000 shares for $5,862.80 on 12/02/2025, 6,528 shares for $17,103.36 on 11/10/2025, and 2,000 shares for $6,141.00 on 11/04/2025, some of which are identified as 10b5-1 sales.
Sera Prognostics, Inc. received an updated large shareholder report showing that Whetstone Capital Advisors, LLC and David Atterbury together beneficially own 3,459,713 shares of its Class A common stock, representing 9.2% of the class. The filing states that the reporting persons share voting and dispositive power over these shares. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Sera Prognostics, but instead are reported on a passive basis under Schedule 13G/A.